Initial and follow up information regarding unsolicited case from United States was received from consumer 
(patient's mother) and transmitted to Sanofi on 02-Apr-2015 (processed together).
This case involves a 02-years-old child patient (gender unknown) for whom reported extra dose administered after 
starting fexofenadine hydrochloride (Allegra Childrens Oral Suspension OTC).
Relevant medical history was unknown.
Concomitant medications: diphenhydramine hydrochloride (Benadryl).
On 02-Apr-2015, the patient started therapy with fexofenadine hydrochloride oral suspension 30mg/5ml twice a day 
(lot number and expiration date: unknown) for allergies (sinus allergies and respiratory symptoms). It patient's 
mother was reported that, "her 2 year old baby was given a second dose of fexofenadine hydrochloride childrens 
suspension by mistake with 12 hours, patient had been giving both diphenhydramine hydrochloride (Benadryl) and 
fexofenadine hydrochloride  for sinus allergies, patient's had an allergic reaction to something and had a rash, he 
also had respiratory symptoms, she decided to give him diphenhydramine hydrochloride for the rash and 
fexofenadine hydrochloride suspension for the respiratory symptoms, she gave him the fexofenadine hydrochloride 
, and then about 8 hours later intended to give him the diphenhydramine hydrochloride but got mixed up and gave 
him another dose of fexofenadine hydrochloride ".
Action taken: not applicable.
The therapy status for fexofenadine hydrochloride was ongoing.
Sanofi causal assessment: unclassified.
No further relevant information was reported.